Retatrutide: The Triple-Agonist That Hit 30% Weight Loss
TRIUMPH-1 Phase 3 data is in. The largest average weight loss ever recorded in a pivotal obesity trial — and the first medication to reach bariatric surgery territory. Here's every number that matters.
On May 21, 2026, Eli Lilly announced topline results from TRIUMPH-1 — the pivotal Phase 3 obesity trial for retatrutide. The headline number: participants on the highest dose lost an average of 28.3% of their body weight at 80 weeks. In the pre-specified 104-week extension for those with BMI ≥35, that figure climbed to 30.3% — an average of 85 pounds.
No medication has ever reached that threshold in a registrational obesity trial. The only interventions that have historically produced weight loss above 30% are bariatric surgical procedures.
Retatrutide isn't approved. It isn't available by prescription. But TRIUMPH-1 provides the pivotal efficacy evidence Eli Lilly needs to file a New Drug Application, and that filing is expected before the end of this year.
What Is Retatrutide?
Retatrutide is a first-in-class investigational peptide that simultaneously activates three hormone receptors:
- GLP-1 (glucagon-like peptide-1) — the mechanism shared with semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound). Reduces appetite, slows gastric emptying, enhances insulin secretion.
- GIP (glucose-dependent insulinotropic polypeptide) — the second mechanism added by tirzepatide. Amplifies the insulin response, may improve fat metabolism, and appears to reduce nausea compared to GLP-1 alone.
- Glucagon — the third receptor, unique to retatrutide. Increases energy expenditure, promotes hepatic fat oxidation, and may directly reduce liver fat accumulation. This is the mechanism that separates retatrutide from everything else on the market.
The glucagon component is what makes retatrutide a "triple agonist" — and may explain both its superior weight loss and its unique signals on liver fat and metabolic endpoints that go beyond what dual agonists achieve.
TRIUMPH-1 Data Breakdown
TRIUMPH-1 enrolled 2,339 adults with obesity or overweight with at least one weight-related comorbidity. Participants were randomized to retatrutide 4 mg, 9 mg, 12 mg (titrated up from 2 mg every four weeks), or placebo. The primary endpoint was percent change in body weight at 80 weeks.
| Dose | Weight Loss at 80 wk | ≥30% Responders | Waist Reduction |
|---|---|---|---|
| Placebo | −3.9% | — | −1.4 inches |
| 4 mg | −17.6% | — | −6.4 inches |
| 9 mg | −23.7% | — | — |
| 12 mg | −25.0% | 45.3% | −9.5 inches |
| 12 mg (104 wk, BMI ≥35) | −30.3% (85 lbs) | — | — |
Two data points stand out. First, the dose-response curve is steep and clean — 4 mg delivers meaningful weight loss (17.6%) with the lowest discontinuation rate, while 12 mg delivers the maximum effect. This gives prescribers a wide therapeutic window. Second, the 104-week extension showed no weight-loss plateau. At the highest dose, weight was still declining at two years. Whether that trend continues or plateaus beyond 104 weeks remains to be seen in longer follow-up.
How Retatrutide Compares
Context matters. Here's how TRIUMPH-1 stacks against the registrational trials for the other major weight-loss medications:
| Drug | Mechanism | Trial | Duration | Weight Loss |
|---|---|---|---|---|
| Retatrutide 12 mg | GIP + GLP-1 + Glucagon | TRIUMPH-1 | 80 wk | −28.3% |
| Tirzepatide 15 mg | GIP + GLP-1 | SURMOUNT-1 | 72 wk | −22.5% |
| Semaglutide 2.4 mg | GLP-1 | STEP-1 | 68 wk | −14.9% |
| Orforglipron 45 mg | GLP-1 (oral) | ATTAIN-1 | 72 wk | −14.7% |
The gap between retatrutide and tirzepatide is roughly 5.8 percentage points. The gap between retatrutide and semaglutide is 13.4 percentage points. These are not head-to-head comparisons — different trials, different populations, different durations — but the pattern is consistent: the triple mechanism produces more weight loss than the dual, which produces more than the single.
Safety Profile
The side effect profile follows the pattern established by GLP-1 class medications, with higher rates of GI symptoms at higher doses:
| Adverse Event | 4 mg | 9 mg | 12 mg | Placebo |
|---|---|---|---|---|
| Nausea | 28.6% | 38.4% | 42.4% | 14.8% |
| Diarrhea | 25.2% | 34.1% | 32.0% | 13.5% |
| Constipation | — | — | 26.1% | — |
| Vomiting | — | — | 25.3% | — |
GI side effects were most common during the dose-escalation phase and generally resolved as treatment continued. Dysesthesia (altered skin sensation) and urinary tract infections were reported in roughly 1 in 10 patients at higher doses — these are symptoms that have been noted across GLP-1 class medications but were generally mild to moderate.
Critically, the discontinuation rate on the 4 mg dose was lower than placebo, suggesting the lowest dose is well-tolerated. This matters for real-world prescribing — not every patient needs or wants the maximum dose.
The TRIUMPH Program
TRIUMPH-1 is one piece of a larger clinical program. Eli Lilly's full TRIUMPH Phase 3 program spans approximately eight trials enrolling over 5,800 participants:
- TRIUMPH-1 (May 2026) — General obesity, pivotal. REPORTED
- TRIUMPH-2 — Obesity with type 2 diabetes. Expected Q3-Q4 2026.
- TRIUMPH-3 — Obesity with established cardiovascular disease. Expected Q3-Q4 2026.
- TRIUMPH-4 (December 2025) — Obesity with knee osteoarthritis. REPORTED — 28.7% weight loss at 68 weeks.
- TRIUMPH-5 — Active comparator trial. Timing not confirmed.
- Additional trials — MASLD/MASH, sleep apnea, and other indications.
Lilly has stated that seven additional Phase 3 readouts are expected in 2026 across the TRIUMPH program. The cardiovascular outcomes data from TRIUMPH-3 will be particularly significant — it's the dataset that determines whether retatrutide receives a cardiovascular risk reduction indication, which would dramatically expand its addressable market and insurance coverage.
FDA Approval Timeline
Based on Lilly's published trial schedule and typical FDA review timelines:
| Milestone | Expected Timing | Status |
|---|---|---|
| TRIUMPH-1 topline results | Q2 2026 | Complete |
| ADA Scientific Sessions presentation | June 2026 | Presented |
| Additional TRIUMPH readouts | Q3-Q4 2026 | Pending |
| NDA submission | Late 2026 – Early 2027 | Expected |
| FDA review period | 10–12 months post-filing | — |
| Potential approval | 2027 – 2028 | — |
The NDA filing is the next critical milestone. Lilly now has the primary efficacy data from TRIUMPH-1 and the osteoarthritis data from TRIUMPH-4. Whether they file before the cardiovascular data is complete, or wait for TRIUMPH-3 to include a broader indication set, will determine whether this is a late-2026 or early-2027 submission.
What This Means for Peptide Therapy
Retatrutide occupies a different space than the peptides typically discussed on this site. It's not a compounding pharmacy product or a research-use compound in the traditional peptide therapy sense. It's a proprietary Eli Lilly drug moving through the standard FDA approval pathway.
But its impact on the broader peptide landscape is significant:
For GLP-1 compounding: The 503B GLP-1 ban already restricted compounded semaglutide. If retatrutide is approved and priced competitively with tirzepatide, it adds another branded option that reduces demand for compounded alternatives — but also creates a new price point for patients to compare against.
For combination protocols: The biohacking community is already discussing stacking research-grade retatrutide with recovery peptides like BPC-157 and TB-500 to manage GI side effects while on GLP-1 class medications. This is off-label territory with no clinical trial support, but it's a trend worth tracking.
For prescribing decisions: When (not if) retatrutide reaches the market, the prescribing landscape for obesity becomes a three-tier system: semaglutide for moderate weight loss and cardiovascular protection, tirzepatide for stronger weight loss with GIP benefits, and retatrutide for maximum weight loss with metabolic liver benefits. The prescribing pathway for each will vary based on insurance coverage, cost, and tolerability.
The Bottom Line
TRIUMPH-1 delivered the largest weight loss ever recorded in a registrational obesity trial. The 30.3% figure at 104 weeks places retatrutide in bariatric surgery territory — a milestone no medication has previously reached. The glucagon receptor component appears to provide metabolic benefits beyond weight loss, particularly for liver fat reduction.
The caveats are real: GI side effects are higher than tirzepatide, the drug is at least a year from potential FDA approval, long-term safety data beyond 104 weeks doesn't exist yet, and pricing and insurance coverage are completely unknown. Retatrutide won't be cheap. Zepbound (tirzepatide) launched at over $1,000/month list price, and retatrutide will likely be priced at a premium to that.
But the trajectory is clear. By the time retatrutide reaches market — likely 2027 or 2028 — obesity pharmacotherapy will offer weight loss results that were previously achievable only through surgery. Whether the healthcare system, insurance infrastructure, and pricing models are ready for that moment is a separate question entirely.